Caxton Associates LP Vanda Pharmaceuticals Inc. Transaction History

Caxton Associates LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$4.28 - $6.57 $647,752 - $994,330	151,344 Added 364.33%	192,884 $833,000
Q2 2023 Aug 14, 2023	SELL	$5.9 - $6.95 $659,879 - $777,315	-111,844 Reduced 72.92%	41,540 $273,000
Q1 2023 May 15, 2023	BUY	$6.18 - $7.99 $146,830 - $189,834	23,759 Added 18.33%	153,384 $1.04 Million
Q4 2022 Feb 14, 2023	BUY	$6.87 - $10.96 $98,062 - $156,443	14,274 Added 12.37%	129,625 $957,000
Q3 2022 Nov 14, 2022	BUY	$9.44 - $11.76 $28,329 - $35,291	3,001 Added 2.67%	115,351 $1.14 Million
Q2 2022 Aug 15, 2022	BUY	$9.31 - $11.84 $661,466 - $841,220	71,049 Added 172.03%	112,350 $1.23 Million
Q1 2022 May 16, 2022	BUY	$10.84 - $16.55 $447,702 - $683,531	41,301 New	41,301 $467,000

156

44.7M

167K

33.6K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $271M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.